Analysts Set Novogen Limited (NASDAQ:KZIA) Price Target at $26.33

Novogen Limited (NASDAQ:KZIA) has received an average rating of “Moderate Buy” from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $26.3333.

Several equities analysts have recently issued reports on KZIA shares. Canaccord Genuity Group initiated coverage on Novogen in a research report on Thursday, August 13th. They set a “buy” rating and a $29.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Novogen in a research note on Friday, July 17th. BTIG Research reaffirmed a “buy” rating and set a $34.00 target price on shares of Novogen in a report on Wednesday, July 15th. Finally, Lake Street Capital initiated coverage on shares of Novogen in a research report on Thursday, June 11th. They issued a “buy” rating and a $32.00 price target on the stock.

Novogen Price Performance

Shares of NASDAQ:KZIA opened at $13.77 on Tuesday. Novogen has a 12 month low of $4.86 and a 12 month high of $17.40. The stock’s 50 day moving average price is $13.47 and its 200 day moving average price is $11.31.

Novogen Company Profile

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.